المؤلفون: Lukiyanov, M, Martsevich, S Y, Pulin, A A, Kutishenko, N P, Andreenko, E Y, Dindikova, V A, Makoveeva, A N, Okshina, E Y, Dmitrieva, N A, Lerman, O V, Voronina, V P, Zagrebelnyy, A V, Klyashtorny, V G, Karpov, O E, Drapkina, O M

المصدر: European Heart Journal ; volume 42, issue Supplement_1 ; ISSN 0195-668X 1522-9645

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Aim To estimate age characteristics, proportion of concomitant cardiovascular diseases (CVD), cardiovascular pharmacotherapy during prehospital period in patients with COVID-19 and community acquired pneumonia (CAP) according the data of hospital registry. Methods The registry included all patients admitted to the special COVID-19 center from April 6 to June 2, 2020 with suspected or confirmed COVID-19 and CAP. This enrollment period was corresponding to the main part of the first epidemic wave of COVID-19 in megapolis (the number of new cases on April 6 and July 2, 2020 was 591 and 662, respectively, the maximal number, 6703 cases, was registered on May 7). COVID-19 was diagnosed in cases of positive polymerase chain reaction test (60.7%) or according to computed tomography data. Results The registry included 1.130 patients (age 57.5±12.8 years, 51.2% men). CAP was diagnosed in 94% of cases, CVD - in 52.9%. Mean age values (from the 1-st up to the 11-th weeks of enrollment period) were, respectively, week by week: 52.8; 54.3; 57.3; 59.6; 56.9; 60.0; 57.2; 62.7; 59.3; 57.4 and 62.2 years (p<0.001; β-coefficient 0.78; 95% Confidential Interval, CI 0.50–1.07). The proportion of patients with CVD was for each of these weeks, respectively: 34.2%; 43.0%; 52.9%; 53.5%; 50.5%; 61.4%; 53.9%; 68.9; 63.1%; 54.8% and 66.7% (p<0.001; Odds Ratio 1.04; 95% CI 1.02–1.06). So, during enrollment period the mean age of patients increased significantly (on average by 0.78 years per week) as well as the proportion of CVD cases increased from 34.2% up to 66.7% (average 51.5%). The mean duration of period from the first day of clinical symptoms until the date of hospitalization was 8.3±5.9 days (median 7; with Q1-Q3 from 5 to 10). There were no significant difference for the length of this period between groups of patients with and without CVD: 8.4±6.2 and 8.3±5.7 days (median 7; with Q1-Q3 from 5 to 10 for both groups), p=0.82; between age groups of ≥65 years and <65 years: 8.8±7.2 and 8.1±5.3 days ...

الإتاحة: https://doi.org/10.1093/eurheartj/ehab724.2734Test
https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2734/41054408/ehab724.2734.pdfTest

المؤلفون: Martsevich, S. Y., Lukina, Y. V., Kutishenko, N. P., Voronina, V. P., Dmitrieva, N. A., Zagrebelniy, A. V., Lerman, O. V., Gaisenok, O. V., Gomova, T. A., Ezhov, A. V., Kuimov, A. D., Libis, R. A., Matyushin, G. V., Mitroshina, T. N., Nechaeva, G. I., Reznik, I. I., Skibitsky, V. V., Chesnikova, A. I., Dobrynina, N. V., Yakushin, S. S., Марцевич, С. Ю., Лукина, Ю. В., Кутишенко, Н. П., Воронина, В. П., Дмитриева, Н. А., Загребельный, А. В., Лерман, О. В., Гайсенок, О. В., Гомова, Т. А., Ежов, А. В., Куимов, А. Д., Либис, Р. А., Матюшин, Г. В., Митрошина, Т. Н., Нечаева, Г. И., Резник, И. И., Скибицкий, В. В., Чесникова, А. И., Добрынина, Н. В., Якушин, С. С.

مصطلحات موضوعية: OBSERVATIONAL STUDY, NICORANDIL, STABLE ANGINA PECTORIS, TREATMENT ADHERENCE, НАБЛЮДАТЕЛЬНОЕ ИССЛЕДОВАНИЕ, НИКОРАНДИЛ, СТАБИЛЬНАЯ СТЕНОКАРДИЯ НАПРЯЖЕНИЯ, ПРИВЕРЖЕННОСТЬ К ЛЕЧЕНИЮ

وصف الملف: application/pdf

العلاقة: Scopus; Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., Воронина В.П., Дмитриева Н.А., Загребельный А.В., Лерман О.В., Гайсенок О.В., Гомова Т.А., Ежов А.В., Куимов А.Д., Либис Р.А., Матюшин Г.В., Митрошина Т.Н., Нечаева Г.И., Резник И.И., Скибицкий В.В., Чесникова А.И., Добрынина Н.В., Якушин С.С. Первые результаты оценки влияния длительного применения никорандила на вероятность возникновения сердечно-сосудистых осложнений у больных стабильной ишемической болезнью сердца (данные наблюдательного исследования НИКЕЯ). Рациональная Фармакотерапия в Кардиологии 2019;15(3):335-342.; http://elib.usma.ru/handle/usma/7331Test

الإتاحة: http://elib.usma.ru/handle/usma/7331Test

المؤلفون: Protasova, D E, Tarasov, A V, Reynbakh, O, Trufanova, E A, Davtyan, K V, Martsevich, S Y

المصدر: European Heart Journal ; volume 39, issue suppl_1 ; ISSN 0195-668X 1522-9645

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الإتاحة: https://doi.org/10.1093/eurheartj/ehy563.p4822Test
http://academic.oup.com/eurheartj/article-pdf/39/suppl_1/ehy563.P4822/25577293/ehy563.p4822.pdfTest

المؤلفون: Akimova, A, Martsevich, S, Kutishenko, N, Lukina, Y U

المصدر: European Heart Journal ; volume 39, issue suppl_1 ; ISSN 0195-668X 1522-9645

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الإتاحة: https://doi.org/10.1093/eurheartj/ehy565.p2862Test
http://academic.oup.com/eurheartj/article-pdf/39/suppl_1/ehy565.P2862/25566306/ehy565.p2862.pdfTest

المؤلفون: Lukiyanov, M M, Yakushin, S S, Zagrebelnyy, A V, Moseichuk, K A, Pravkina, E A, Deev, A D, Kudryashov, E V, Martsevich, S Y U, Vorobyev, A N, Kozminsky, A N, Pereverseva, K G, Andreenko, E Y U, Klyashtorny, V G, Drapkina, O M, Boytsov, S A

المصدر: European Heart Journal ; volume 39, issue suppl_1 ; ISSN 0195-668X 1522-9645

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الإتاحة: https://doi.org/10.1093/eurheartj/ehy566.p6576Test
http://academic.oup.com/eurheartj/article-pdf/39/suppl_1/ehy566.P6576/25577930/ehy566.p6576.pdfTest

المؤلفون: Martsevich, S. Y., Lukina, Y. V., Kutishenko, N. P., Akimova, A. V., Voronina, V. P., Lerman, O. V., Gaisenok, O. V., Gomova, T. A., Ezhov, A. V., Kuimov, A. D., Libis, R. A., Matyushin, G. V., Mitroshina, T. N., Nechaeva, G. I., Reznik, I. I., Skibitsky, V. V., Sokolova, L. A., Chesnikova, A. I., Dobrynina, N. V., Yakushin, S. S., Марцевич, С. Ю., Лукина, Ю. В., Кутишенко, Н. П., Акимова, А. В., Воронина, В. П., Лерман, О. В., Гайсенок, О. В., Гомова, Т. А., Ежов, А. В., Куимов, А. Д., Либис, Р. А., Матюшин, Г. В., Митрошина, Т. Н., Нечаева, Г. И., Резник, И. И., Скибицкий, В. В., Соколова, Л. А., Чесникова, А. И., Добрынина, Н. В., Якушин, С. С.

مصطلحات موضوعية: STABLE ISCHEMIC HEART DISEASE, EFFORT ANGINA, ADHERENCE, NICORANDIL, СТАБИЛЬНАЯ ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА, СТЕНОКАРДИЯ НАПРЯЖЕНИЯ, ПРИВЕРЖЕННОСТЬ, НИКОРАНДИЛ

وصف الملف: application/pdf

العلاقة: Scopus; Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., Акимова А.В., Воронина В.П., Лерман О.В., Гайсенок О.В., Гомова Т.А., Ежов А.В., Куимов А.Д., Либис Р.А., Матюшин Г.В., Митрошина Т.Н., Нечаева Г.И., Резник И.И., Скибицкий В.В., Соколова Л.А., Чесникова А.И., Добрынина Н.В., Якушин С.С. Оценка приверженности к лечению и факторов, влияющих на нее, у пациентов со стабильной ишемической болезнью сердца при назначении никорандила. Рациональная Фармакотерапия в Кардиологии 2017;13(6):776-786.; http://elib.usma.ru/handle/usma/7145Test

الإتاحة: http://elib.usma.ru/handle/usma/7145Test

المؤلفون: Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., le Roux, Carel W., Ortiz, Violante, Jensen, Christine Bjorn, Wilding, John P. H., Hamann A, Barakat A, Blüher M, Linn T, DALLE MOLLE, ALBERTO, Segner A, Stübler P, Tosch-Sisting R, Pacini F, Santini F, Marchesini G, Rotella CM, Invitti C, Vettor R, Buscemi S, Raya PM, Freijoo FC, de Barbará RG, Carraro R, Bobillo ER, de la Cuesta C, Farsang C, Csaszar A, Zahorska-Markiewicz B, Pupek-Musialik D, Franek E, Ostrowska L, Olszanecka-Glinianowicz M, Lalic N, Micic D, Ludvik B, Paulweber B, Prager R, Scheen A, Van Gaal L, Astrup AV, Hermansen K, Madsbad S, Rissanen A, Nieminen S, Savolainen M, Krempf M, Romon M, Laville M, Marre M, Mira R, Finucane F, Veenendaal A, van Berkum F, Johannsson-Vidarsdóttir S, Van de Walle V, Meesters E, Hjelmesæth J, Klemsdal TO, Kulseng B, Bach-Kliegel B, Laederach K, Villiger L, Golay A, Bilz S, Sathyapalan T, Bain S, Kumar S, Le Roux CW, Lean ME, McGowan B, Rehman T, Wilding J, Wittert G, Caterson I, Proietto J, Prins J, Geloneze Neto B, Gross JL, Chacra AR, Halpern A, Suplicy Hde A, Chow FC, Thacker HP, Chadha M, Chandalia H, Unnikrishnan A, Kalra S, Deshpande N, Shunmugavelu M, Deshmukh VC, Maislos M, Lieberman GS, Shimon I, Stern N, Nabriski D, Karnieli E, Shehadeh N, Gonzalez-Galvez G, Arechavaleta-Granell Mdel R, Violante Ortiz RM, Franco GM, Gurieva I, Suplotova LA, Troshina E, Ruyatkina LA, Voychik EA, Martsevich S, Startseva MA, Seeber ME, Badat A, Ellis G, Altuntas Y, Guler S, Ulgen E, Delibasi T, Chetty T, Hart R, Janzen J, Labonte I, Lau D, Liutkus J, O'Keefe D, Padwal R, Ransom TP, Tytus R, Weisnagel SJ, Adler J, Aqua K, Aronoff SL, Bedel GW, Blevins TC, Blumenau J, Brockmyre AP, Call RS, Canadas R, Chaykin LB, Cohen K, Conrow JK, Davis MG, Downey HJ, Drosman SR, Duckor S, Farmer H, Farrell J, Fehnel S, Finneran MP, Forbes R, Forker A, Fredrick M, Fujioka K, Geller SA, Gill S, Glaser L, Greco SN, Greenway FL, Harper W, Herman L, Hoekstra J, Ingebretsen R, Ison R, Jain RK, Kaplan R, Kaster SR, Haase GA, Kerzner B, Kirstein JL, Koltun W, Krieger DR, Lewis CE, Madder R, Marple RN, McDermott EJ, Mello CJ, Miller AB, Mullen J, Nardandrea J, O'Neil P, Pi-Sunyer F, Pucillo RM, Rhee C, Redrick S, Pardini A, Rothman J, Rubino DM, Sellers G, Smith T, Byars WD, Soufer J, Sussman AM, Patrick K, Schramm EL, Van Cleeff M, Berg SR, Wyatt HR, Simon JA.

المساهمون: Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., le Roux, Carel W., Ortiz, Violante, Jensen, Christine Bjorn, Wilding, John P. H., Hamann, A, Barakat, A, Blüher, M, Linn, T, DALLE MOLLE, Alberto, Segner, A, Stübler, P, Tosch-Sisting, R, Pacini, F, Santini, F, Marchesini, G, Rotella, Cm, Invitti, C, Vettor, R, Buscemi, S, Raya, Pm, Freijoo, Fc, de Barbará, Rg, Carraro, R, Bobillo, Er, de la Cuesta, C, Farsang, C, Csaszar, A, Zahorska-Markiewicz, B, Pupek-Musialik, D, Franek, E, Ostrowska, L, Olszanecka-Glinianowicz, M, Lalic, N, Micic, D, Ludvik, B, Paulweber, B, Prager, R, Scheen, A, Van Gaal, L, Astrup, Av, Hermansen, K, Madsbad, S, Rissanen, A, Nieminen, S, Savolainen, M, Krempf, M, Romon, M, Laville, M, Marre, M, Mira, R, Finucane, F, Veenendaal, A, van Berkum, F, Johannsson-Vidarsdóttir, S, Van de Walle, V, Meesters, E, Hjelmesæth, J, Klemsdal, To, Kulseng, B, Bach-Kliegel, B, Laederach, K, Villiger, L, Golay, A, Bilz, S, Sathyapalan, T, Bain, S, Kumar, S, Le Roux, Cw, Lean, Me, Mcgowan, B, Rehman, T, Wilding, J, Wittert, G, Caterson, I, Proietto, J, Prins, J, Geloneze Neto, B, Gross, Jl, Chacra, Ar, Halpern, A, Suplicy Hde, A, Chow, Fc, Thacker, Hp, Chadha, M, Chandalia, H, Unnikrishnan, A, Kalra, S, Deshpande, N, Shunmugavelu, M, Deshmukh, Vc, Maislos, M, Lieberman, G, Shimon, I

مصطلحات موضوعية: Adult, Blood Glucose, Body Mass Index, Combined Modality Therapy, Counseling, Diarrhea, Diet, Reducing, Double-Blind Method, Exercise, Female, Glucagon-Like Peptide 1, Human, Hypoglycemic Agent, Injections, Subcutaneou, Liraglutide, Male, Middle Aged, Nausea, Obesity, Weight Lo, Medicine (all)

الوصف: BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS In this study, 3.0 mg of liraglutide, as an ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26132939; info:eu-repo/semantics/altIdentifier/wos/WOS:000357218700004; volume:373; issue:1; firstpage:11; lastpage:22; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11568/855260Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84936166069

الإتاحة: https://doi.org/10.1056/NEJMoa1411892Test
http://hdl.handle.net/11568/855260Test

المؤلفون: West, C, Garcia-Aranda Dominguez, B, Alonso-Gonzalez, R, Li, W, Uebing, A, Cruz, C, Lebreiro, A, Pinho, T, Dias, C, Silva Cardoso, J, Julia Maciel, M, Pirat, B, Varan, B, Erdogan, I, Sade, LE, Muderrisoglu, H, Mateescu, A, Enache, R, Nastase, O, Botezatu, D, Popescu, BA, Ginghina, C, Di Salvo, G, D'aiello, AF, Del Gaizo, F, Rea, A, Capogrosso, C, Russo, MG, Capotosto, L, D'angeli, I, Placanica, A, Ashurov, R, Placanica, G, Tanzilli, G, Mangieri, E, Vitarelli, A, Grosse-Wortmann, L, Compton, G, Dragulescu, A, Nield, L, Ierano, P, Esposito, R, Santoro, C, De Stefano, F, Muscariello, R, Buonauro, A, Tufano, A, Galderisi, M, Cantinotti, M, Assanta, N, Crocetti, M, Marotta, M, Scalese, M, Molinaro, S, Murzi, B, De Lucia, V, Spadoni, I, Iervasi, G, Gaisenok, O, Martsevich, S YU, Deev, A D

مصطلحات موضوعية: Thursday 14 December 2014

الوصف: Aim: There is wealth of data on the echocardiographic evaluation of prosthetic valves in the aortic or mitral position. Similar data are missing for the Melody percutaneous pulmonary valve system (MPPV). We aimed to correlate the anatomic appearance of the MPPV with the haemodynamic result on invasive and echocardiographic assessment. Patients and Methods: All 45 patients who underwent MPPV implantation at our institution between 2007-2013 were studied (median age 30 [range 11-61] years). All patients had complex congenital heart disease. The narrowest dimensions of the MPPV system were taken from the final biplane orthogonal fluoroscopic images to calculate the effective valve opening area (EOA). The post implantation invasive peak-to-peak gradient (ΔPp-p) and the maximal and mean Doppler gradient (ΔPmax and ΔPmean) on the pre-discharge echocardiogram (within 72 hours of implantation) were also obtained. Results: ΔPp-p after valve implantation was low (11.5±5.2 [range 2-20] mmHg) and there was no significant residual pulmonary regurgitation. The peak and mean gradient across the valve by Doppler assessment were significantly higher than ΔPp-p (ΔPmean: 19.3±6.5, ΔPmax: 33.3±8.2 mmHg; P<0.0001 for both vs. ΔPp-p). Both Doppler gradients correlated significantly with the invasive peak gradient (ΔPp-p vs. ΔPmean: r=0.37, P=0.03; ΔPp-p vs. ΔPmax: r=0.39, P=0.02) The EOA of the valve system indexed to body surface area was 132±30 mm2/m2. There were only weak relationships between the indexed EOA and the invasive and Doppler gradients (correlations with EOA: ΔPp-p: r=-0.32, P=0.06; ΔPpeak: r=-0.33, P=0.045; ΔPmean: r=-0.23; P=0.16). Conclusion: Doppler assessment of the percutaneous Melody valve early after implantation consistently overestimates the invasive peak-to-peak gradient. Simple estimates of valve size do not allow prediction of central haemodynamics. These results reflect the complex and variable anatomy of the right ventricular outflow tract/ main pulmonary artery in this group of patients.

وصف الملف: text/html

العلاقة: http://ehjcimaging.oxfordjournals.org/cgi/content/short/15/suppl_2/ii78Test; http://dx.doi.org/10.1093/ehjci/jeu254Test

الإتاحة: https://doi.org/10.1093/ehjci/jeu254Test
http://ehjcimaging.oxfordjournals.org/cgi/content/short/15/suppl_2/ii78Test

المؤلفون: Oganov, R. G., Kukharchuk, V. V., Arutyunov, G. P., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Karpov, Yu. A., Kobalava, Zh. D., Konstantinov, V. O., Martsevich, S. Yu., Panov, A. V., Sergienko, I. V., Skibitskyi, V. V., Smolenskaya, O. G., Susekov, A. V., Tyurin, V. P., Shalaev, S. V., Maneshina, O. A., Brigida, O. V., Оганов, Р. Г., Кухарчук, В. В., Арутюнов, Г. П., Галявич, А. С., Гуревич, В. С., Дупляков, Д. В., Карпов, Ю. А., Кобалава, Ж. Д., Константинов, В. О., Марцевич, С. Ю., Панов, А. В., Сергиенко, И. В., Скибицкий, В. В., Смоленская, О. Г., Сусеков, А. В., Тюрин, В. П., Шалаев, С. В., Манешина, О. А., Бригида, О. В.

مصطلحات موضوعية: CARDIOVASCULAR DISEASE, CROSS-SECTIONAL STUDY, DYSISRUSSIA STUDY, DYSLIPIDEMIA, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, HYDROXYL-METHYLGLUTARYL COA REDUCTASE INHIBITORS, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, RISK, TRIGLYCERIDES, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, КРОСС-СЕКЦИОННОЕ ИССЛЕДОВАНИЕ, ИССЛЕДОВАНИЕ DYSIS-RUSSIA, ДИСЛИПИДЕМИЯ, ХОЛЕСТЕРИН ЛИПОПРОТЕИНОВ ВЫСОКОЙ ПЛОТНОСТИ, ИНГИБИТОРЫ ГИДРОКСИМЕТИЛГЛЮТАРИЛ-COA-РЕДУКТАЗЫ, ХОЛЕСТЕРИН ЛИПОПРОТЕИНОВ НИЗКОЙ ПЛОТНОСТИ, РИСК, ТРИГЛИЦЕРИДЫ

وصف الملف: application/pdf

العلاقة: Scopus; Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS) / Р. Г. Оганов, В. В. Кухарчук, Г. П. Арутюнов [и др.] //Кардиоваскулярная терапия и профилактика. – 2012. - 11(4). – с. 70-78.; http://elib.usma.ru/handle/usma/6956Test

الإتاحة: http://elib.usma.ru/handle/usma/6956Test

المؤلفون: Egorov, V., Shilova, E., Martsevich, S.

مصطلحات موضوعية: СТАБИЛЬНАЯ СТЕНОКАРДИЯ, ИЗОСОРБИДА ДИНИТРАТ, ИЗОСОРБИД-5-МОНОНИТРАТ, ISOSORBIDE-5-MONONITRATE. RATIONAL PHARMACOTHER

الوصف: Aim. To study efficacy and tolerability of isosorbide-5-mononitrate (IMN) in various presentations in comparison with isosorbide dinitrate (IDN) in usual tablets in patients with stable angina. Material and Methods. 22 patients (5 women and 17 men) with stable angina of II-III functional class were involved into open randomized comparative crossover study. Patients were splitin 3groups and received each of studied drugs during 4 weeks. IDN (Nitrosorbide, Nizpharm, Russia) in usual tablets10 mg prescribed for 3 times a day administration; IMN (Monocinque,Berlin-Chemie, German) in tablets 20 mg prescribed for 2 times a day administration. After 1 week therapy the doses of IDN or IMN doubled if it was clinically necessary. Retarded presentation of IMN (Monocinque Retard, Berlin-Chemie, German) in capsules 50 mg prescribed once daily. Drug efficacy was evaluated by changes in clinical symptoms, number of angina attacks, demand in short-acting sublingual nitroglycerin as well as physical activity tolerance. Results. After4 weeks18patients completed study, 2patients dropped out becauseofprotocol nonobservance and2patients dropped out becauseofside effects (headache). IDN therapy in adjusted dose provided antianginal effect in 15 (83,3%) patients: a number of angina attacks decreased in 39,6%, short-acting nitroglycerin demand reduced in 47,7%. Monocinque in adjusted dose provided antianginal effect in 16 (88,9%) patients: a number of angina attacks decreased in 60%, short-acting nitroglycerin demand reduced in 63%. Monocinque Retard provided good antianginal effect in 18 (100%) patients: a number of angina attacks decreased in 72%, short-acting nitroglycerin demand reduced in 84,8%. There were not significant differences in frequency and severity of headache between studied drugs. Conclusion. IMN therapy with both presentations (administrated 1 or 2 times a day) was more convenient and effective than IDN (administrated 3 times a day).

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/vybor-terapii-nitratami-u-bolnyh-stabilnoy-stenokardiey-napryazheniya-sravnitelnoe-issledovanie-obychnyh-tabletok-izosorbidaTest
http://cyberleninka.ru/article_covers/9415836.pngTest